| 引用本文: | 潘云龙,王晶,罗芳,吴丹,张建康,祝华建,邵加安.基于低氧微环境的小分子激活前药与HIF-1抑制剂研究进展[J].中国现代应用药学,2023,40(12):1738-1752. |
| PAN Yunlong,WANG Jing,LUO Fang,WU Dan,ZHANG Jiankang,ZHU Huajian,SHAO Jia'an.Research Progress in the Study of Small Molecule Hypoxia-activated Prodrugs and HIF-1 Inhibitors Based on Hypoxia Microenvironment[J].Chin J Mod Appl Pharm(中国现代应用药学),2023,40(12):1738-1752. |
|
| |
|
|
| 本文已被：浏览 3686次 下载 1594次 |
码上扫一扫！ |
|
|
| 基于低氧微环境的小分子激活前药与HIF-1抑制剂研究进展 |
|
潘云龙1,2, 王晶2, 罗芳1,2, 吴丹1,2, 张建康2, 祝华建2, 邵加安2
|
|
1.浙江工业大学药学院, 杭州 310014;2.浙大城市学院医学院, 杭州 310015
|
|
| 摘要: |
| 低氧是实体瘤普遍存在的特征，是肿瘤细胞增殖、转移、侵袭、产生放疗抗性的重要原因。因此，肿瘤缺氧被认为是肿瘤诊断与治疗的一个重要靶点。低氧激活前药可在缺氧微环境下通过电子还原靶向低氧区域的肿瘤细胞，产生并释放细胞毒性代谢产物，从而杀死肿瘤细胞。目前已报道的低氧激活前药主要包括硝基化合物、醌类、氮氧化物、金属配合物、偶氮化合物五大类。而低氧诱导因子-1(hypoxia-inducible factor-1，HIF-1)也在肿瘤细胞的低氧存活与发展中扮演重要角色，抑制HIF-1可抑制其下游基因主导的肿瘤血管生成、转移、耐药等生存发展进程。当前，已有低氧激活前药与HIF-1抑制剂正处于临床试验阶段，并表现出良好的抗肿瘤活性，并有可能在未来的肿瘤诊断与治疗中发挥重要作用。 |
| 关键词: 肿瘤缺氧 低氧靶向 低氧激活前药 HIF-1抑制剂 |
| DOI：10.13748/j.cnki.issn1007-7693.20223610 |
| 分类号:R914 |
| 基金项目: |
|
| Research Progress in the Study of Small Molecule Hypoxia-activated Prodrugs and HIF-1 Inhibitors Based on Hypoxia Microenvironment |
|
PAN Yunlong1,2, WANG Jing2, LUO Fang1,2, WU Dan1,2, ZHANG Jiankang2, ZHU Huajian2, SHAO Jia'an2
|
|
1.School of Pharmacy, Zhejiang University of Technology, Hangzhou 310014, China;2.School of Medicine, Hangzhou City University, Hangzhou 310015, China
|
| Abstract: |
| Hypoxia is a prevalent feature of solid tumors and it is an important cause of tumor cell proliferation, metastasis, invasion, and development of resistance to radiotherapy. Therefore, tumor hypoxia is considered to be an important target for cancer diagnosis and treatment. Hypoxia-activated prodrugs can kill tumor cells by targeting tumor cells in hypoxic regions via electron reduction in a hypoxic microenvironment to produce and release cytotoxic metabolites. Currently, five major classes of hypoxia-activated prodrugs have been reported, including nitro compounds, quinones, nitrogen oxides, metal complexes, and azo compounds. The hypoxia-inducible factor-1(HIF-1) also plays an important role in the hypoxic survival and development of tumor cells, and inhibition of HIF-1 can inhibit its downstream gene-driven tumor angiogenesis, metastasis, drug resistance and other survival development processes. Currently, hypoxia-activated prodrugs with HIF-1 inhibitors are in clinical trials and have shown good anti-tumor activity and may play an important role in tumor diagnosis and treatment in the future. |
| Key words: tumor hypoxia hypoxia targeting hypoxia-activated prodrugs HIF-1 inhibitors |
|
|
|
|
